RecruitingNCT05634928

Construction of a Database for TMA

Construction of a Database for Thrombotic Microangiopathy

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment

500 participants

Start Date

Dec 1, 2022

Study Type

OBSERVATIONAL

Conditions

Thrombotic Microangiopathies

Summary

Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Dec 1, 2022, to Nov 31, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical-related data of thrombotic microangiopathy.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is building a registry (database) of patients with a condition called thrombotic microangiopathy (TMA) — a serious disorder where tiny blood clots form throughout small blood vessels, damaging red blood cells and organs. By collecting data from many patients, researchers hope to better understand TMA and improve future treatments. You may be eligible if... - Your lab results show signs of TMA: high LDH levels, very low or rapidly falling platelets, and fragmented red blood cells (schistocytes) visible on a blood test, OR your tissue biopsy shows widespread micro-clots - You are willing and able to cooperate with study procedures You may NOT be eligible if... - Your doctor believes you are unable or unwilling to cooperate with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.